K W Miskowiak1, M Vinberg1, L Glerup1, O B Paulson2, G M Knudsen3, H Ehrenreich4, C J Harmer5, L V Kessing1, H R Siebner2, J Macoveanu1. 1. Psychiatric Centre Copenhagen,Copenhagen University Hospital,Rigshospitalet,Copenhagen,Denmark. 2. Danish Research Centre for Magnetic Resonance (DRCMR),Centre for Functional and Diagnostic Imaging and Research,Hvidovre Hospital, University of Copenhagen,Copenhagen,Denmark. 3. Center for Integrated Molecular Brain Imaging,Rigshospitalet,Copenhagen,Denmark. 4. Division of Clinical Neuroscience,Max Planck Institute of Experimental Medicine,Göttingen,Germany. 5. Department of Psychiatry,University of Oxford,Oxford,UK.
Abstract
BACKGROUND: Cognitive dysfunction in depression and bipolar disorder (BD) is insufficiently targeted by available treatments. Erythropoietin (EPO) increases neuroplasticity and may improve cognition in mood disorders, but the neuronal mechanisms of these effects are unknown. This functional magnetic resonance imaging (fMRI) study investigated the effects of EPO on neural circuitry activity during working memory (WM) performance. METHOD: Patients with treatment-resistant major depression, who were moderately depressed, or with BD in partial remission, were randomized to eight weekly infusions of EPO (40 000 IU) (N = 30) or saline (N = 26) in a double-blind, parallel-group design. Patients underwent fMRI, mood ratings and blood tests at baseline and week 14. During fMRI patients performed an n-back WM task. RESULTS:EPO improved WM accuracy compared with saline (p = 0.045). Whole-brain analyses revealed that EPO increased WM load-related activity in the right superior frontal gyrus (SFG) compared with saline (p = 0.01). There was also enhanced WM load-related deactivation of the left hippocampus in EPO-treated compared to saline-treated patients (p = 0.03). Across the entire sample, baseline to follow-up changes in WM performance correlated positively with changes in WM-related SFG activity and negatively with hippocampal response (r = 0.28-0.30, p < 0.05). The effects of EPO were not associated with changes in mood or red blood cells (p ⩾0.08). CONCLUSIONS: The present findings associate changes in WM-load related activity in the right SFG and left hippocampus with improved executive function in EPO-treated patients. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov: NCT00916552.
RCT Entities:
BACKGROUND:Cognitive dysfunction in depression and bipolar disorder (BD) is insufficiently targeted by available treatments. Erythropoietin (EPO) increases neuroplasticity and may improve cognition in mood disorders, but the neuronal mechanisms of these effects are unknown. This functional magnetic resonance imaging (fMRI) study investigated the effects of EPO on neural circuitry activity during working memory (WM) performance. METHOD:Patients with treatment-resistant major depression, who were moderately depressed, or with BD in partial remission, were randomized to eight weekly infusions of EPO (40 000 IU) (N = 30) or saline (N = 26) in a double-blind, parallel-group design. Patients underwent fMRI, mood ratings and blood tests at baseline and week 14. During fMRI patients performed an n-back WM task. RESULTS:EPO improved WM accuracy compared with saline (p = 0.045). Whole-brain analyses revealed that EPO increased WM load-related activity in the right superior frontal gyrus (SFG) compared with saline (p = 0.01). There was also enhanced WM load-related deactivation of the left hippocampus in EPO-treated compared to saline-treated patients (p = 0.03). Across the entire sample, baseline to follow-up changes in WM performance correlated positively with changes in WM-related SFG activity and negatively with hippocampal response (r = 0.28-0.30, p < 0.05). The effects of EPO were not associated with changes in mood or red blood cells (p ⩾0.08). CONCLUSIONS: The present findings associate changes in WM-load related activity in the right SFG and left hippocampus with improved executive function in EPO-treated patients. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov: NCT00916552.
Authors: Kyoko Konishi; Sara Cherkerzian; Sarah Aroner; Emily G Jacobs; Dorene M Rentz; Anne Remington; Harlyn Aizley; Mady Hornig; Anne Klibanski; Jill M Goldstein Journal: Neurobiol Aging Date: 2019-12-24 Impact factor: 4.673
Authors: Lars Vedel Kessing; Klaus Munkholm; Maria Faurholt-Jepsen; Kamilla Woznica Miskowiak; Lars Bo Nielsen; Ruth Frikke-Schmidt; Claus Ekstrøm; Ole Winther; Bente Klarlund Pedersen; Henrik Enghusen Poulsen; Roger S McIntyre; Flavio Kapczinski; Wagner F Gattaz; Jakob Bardram; Mads Frost; Oscar Mayora; Gitte Moos Knudsen; Mary Phillips; Maj Vinberg Journal: BMJ Open Date: 2017-06-23 Impact factor: 2.692
Authors: Lauren L Jantzie; Akosua Y Oppong; Fatu S Conteh; Tracylyn R Yellowhair; Joshua Kim; Gabrielle Fink; Adam R Wolin; Frances J Northington; Shenandoah Robinson Journal: Front Neurol Date: 2018-04-13 Impact factor: 4.003
Authors: Caroline V Ott; Maj Vinberg; Christopher R Bowie; Ellen Margrethe Christensen; Gitte M Knudsen; Lars V Kessing; Kamilla W Miskowiak Journal: Trials Date: 2018-09-12 Impact factor: 2.279